NCT04598009View on ClinicalTrials.gov

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Melanoma Stage IIIMelanoma Stage IV
Interventions
DRUG

Binimetinib

Taken orally (PO) twice a day (BID)

DRUG

Imatinib

Taken orally (PO) once a day (QD)

Trial Locations (2)

92093

RECRUITING

UC San Diego Moores Cancer Center, La Jolla

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Array BioPharma
All Listed Sponsors
collaborator

Array BioPharma

INDUSTRY

lead

University of California, San Francisco

OTHER